This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.

Kaye Scholer Represents Sandoz in Tech Agreement for Long-Acting Injectable Oncology Product…

February 16, 2016

Kaye Scholer represented Novartis subsidiary Sandoz, a world leader in generic pharmaceuticals, in a collaboration agreement with biotechnology company MedinCell. Under terms of the agreement, which was announced February 4, the alliance will develop and commercialize long-acting injectable drug products based on BEPO™ technology, with a primary focus on oncology.

The technology to deliver long-acting injectable drugs is rapidly advancing the world of pharmacology. The ability to provide a subcutaneous controlled release of drugs for days, weeks or even months has the potential to offer significant advantages over current delivery mechanisms, including patient compliance with a prescription regimen, efficacy and tolerability.

Corporate partner Aaron Gardner represented Sandoz in this transaction.

» Read more about the agreement.

Also of Interest